Gut microbiota in colorectal cancer development and therapy

Selection of GalNAc-Conjugated siKeap1 as Disease-Specific Delivery System for Chemotherapy-Induced Liver Injury and Chronic Liver Disease

“…34,35 The administration of chemotherapy drugs can disrupt and alter microbial communities, and mounting evidence suggests that the gut microbiota plays a role in shaping the therapeutic responses of patients to chemotherapy. 36,37 To investigate the potential impact of siKeap1-GalNAc on gut microbiota, we collected fecal samples and conducted 16S rRNA gene sequencing analysis targeting the V4 regions to investigate the composition of the host microbiota. Our analysis revealed that the treatment with OXA was associated with a decrease in microbial diversity, as indicated by reduced Shannon entropy.…”

“…The trillions of microorganisms in the intestine are important regulators of health, and the disruption of the gut microbiota homeostasis can interplay with liver diseases . By regulating the gut–liver axis, gut microbiota has emerged as a key player in liver diseases, including nonalcoholic fatty liver disease, alcohol-associated liver disease, cirrhosis, and hepatocellular carcinoma. , The administration of chemotherapy drugs can disrupt and alter microbial communities, and mounting evidence suggests that the gut microbiota plays a role in shaping the therapeutic responses of patients to chemotherapy. , To investigate the potential impact of si Keap1 -GalNAc on gut microbiota, we collected fecal samples and conducted 16S rRNA gene sequencing analysis targeting the V4 regions to investigate the composition of the host microbiota. Our analysis revealed that the treatment with OXA was associated with a decrease in microbial diversity, as indicated by reduced Shannon entropy.…”

Recent progress in nanomaterials for bacteria-related tumor therapy

“…For example, rectal tumors predominantly harbor Firmicutes and Bacteroidetes. 25 Pancreatic cancer exhibits a dominance of Proteus akin to the normal duodenal microbiome, possibly indicating bacterial migration from the duodenum through the pancreatic duct. 3,26 Proteobacteria and Firmicutes are present across all cancer types, while their ratio (P/F) varies among tumors, potentially holding significance in understanding individual cancer microbiomes.…”

Oral Nanomedicine: Challenges and Opportunities

“…As the GIT with a peaceful gut lumen is rich in microflora, the disturbance of gut flora is closely related to the onset and deterioration of colorectal cancer (CRC). [ 120–122 ] Differing from traditional medical delivery, gut microbiome‐targeted therapy plays a superior role in accumulating medicines in lesion sites orally administered because it does not need to penetrate through the intestinal epithelial barriers. For instance, to cope with the stress from hostile acidic and multi‐enzyme environments in GIT, Zheng et al.…”